WilmerHale Advises Akebia Therapeutics in $50M Public Offering

WilmerHale Advises Akebia Therapeutics in $50M Public Offering

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On March 19, 2025, Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced the pricing of its underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. The gross proceeds to Akebia from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.

The WilmerHale team representing Akebia included Stuart Falber, Caroline Dotolo, Katharine Patterson, Rachael Joseph and Whitley Horning.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel